Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs delivers cutting-edge recombinant antibodies specifically designed to target CD33, offering powerful tools for advancing biomedical research. Our dedication to supporting research and discovery is reflected in our diverse portfolio of high-quality recombinant products, crafted to meet the stringent requirements of scientists. We focus on delivering exceptional value, combining superior performance with cost-effectiveness. In addition to our premium antibody offerings, we provide expert technical support to help researchers enhance their experimental outcomes. Partnering with Creative Biolabs means accessing innovative solutions that drive scientific progress and foster impactful advancements in the biomedical field.
CD33 is a cell surface receptor found on various cells, especially in certain diseases, where it plays a crucial role in the development and progression of hematological malignancies, including acute myeloid leukemia (AML). Its presence in leukemia cells makes CD33 an ideal target for therapeutic approaches. In clinical research, targeting CD33 has shown significant promise, offering potential treatments for AML. Monoclonal antibodies and antibody-drug conjugates targeting CD33 are being developed and tested in clinical trials, with the goal of selectively targeting and eliminating leukemia cells, offering a more focused and potentially less toxic alternative to traditional chemotherapy. Moreover, further understanding of CD33's involvement in disease mechanisms, as well as its interactions within the tumor microenvironment, could pave the way for combination therapies that improve treatment outcomes and enhance the effectiveness of existing therapies.
CD33 molecule, CD33rSiglec, SIGLEC-3, SIGLEC3, p67
Sialic-acid-binding immunoglobulin-like lectin (Siglec) plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or sialylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through the dephosphorylation of signaling molecules. One of the repressive effects of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K.
We provide premium anti-CD33 recombinant antibodies to support and accelerate research focused on the CD33 target in biological studies.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MOB-1148z | Mouse Anti-CD33 Recombinant Antibody (clone 19C9) | Human | Mouse | ELISA; FC; IF; IHC; IP; FuncS |
TAB-119LC | Mouse Anti-CD33 Recombinant Antibody | Human | Mouse | ELISA; IF; RIA |
HPAB-0083-LSX | Human Anti-CD33 Recombinant Antibody | Human; Cynomolgus monkey | Human | ELISA; FC |
HPAB-1948LY | Human Anti-CD33 Recombinant Antibody | Human; Mouse | Human | FC; SPR; Block |
TAB-H37 | Anti-Human CD33 Recombinant Antibody (Gemtuzumab Ozogamicin) | Human | Human | ELISA; FC; IP; FuncS; IF; Neut; IHC |
To meet customer needs, we have implemented a robust quality management system that guarantees the excellence of our products while offering exceptional technical support to our clients.
Fig.1 SDS-PAGE analysis of anti-CD33 antibody
(Cat# HPAB-0083-LSX, Creative Biolabs).
Fig.2 SEC-HPLC analysis of anti-CD33 antibody
(Cat# HPAB-0083-LSX, Creative Biolabs).
Fig.3 DB analysis of anti-CD33 antibody
(Cat# HPAB-0083-LSX, Creative Biolabs).
Fig.4 ELISA analysis of anti-CD33 antibody
(Cat# HPAB-0083-LSX, Creative Biolabs).
Fig.5 WB analysis of anti-CD33 antibody
(Cat# TAB-119LC, Creative Biolabs).
With years of expertise in recombinant antibody production and optimization, our company delivers high-quality products in a timely manner. We are committed to providing top-tier recombinant antibodies, adhering to the highest production standards and offering exceptional customer service throughout the process.
Featured Anti-CD33 Recombinant Antibody Production Platforms
Fig.6 Milligram-scale recombinant antibody production.
Fig.7 Gram-scale recombinant antibody production.
Creative Biolabs is committed to providing researchers with a broad selection of high-quality recombinant antibodies in diverse formats. These include, but are not limited to, full-length, Fab, scFv, scFab, and full-length antibodies with various Fc isotypes. Our expertise spans a wide array of recombinant antibody engineering techniques, and we offer exceptional custom engineering services tailored to meet your specific requirements.
Fig.8 Diverse anti-CD33 recombinant antibody production and modalities.
Table 1. Therapeutic approaches targeting CD33 in clinical development.
Research phase | Company | Classification | Indications | Details |
Launched - 2000 | Celltech | Drug Conjugates | Acute myeloid leukemia | It is an anti-CD33 humanized antibody linked with calicheamicin, a potent antitumor antibiotic isolated by Wyeth Pharmaceuticals (now Pfizer) from a bacterium in caliche clay, a soil found in Texas. |
Phase II | Actinium Pharmaceuticals | Drug Conjugates | Acute myeloid leukemia | It is an actinium-radiolabeled humanized monoclonal antibody targeting CD33, is in phase II clinical development at Actinium Pharmaceuticals for the treatment of patients 60 years and older with newly diagnosed acute myeloid leukemia (AML). |
Phase I/II | Actinium Pharmaceuticals | Drug Conjugates | Acute myeloid leukemia | It is a humanized monoclonal antibody targeting CD33 (HuM195) that has completed early clinical trials by Actinium Pharmaceuticals and Memorial Sloan-Kettering Cancer Center for the treatment of acute myeloid leukemia. |
Phase I | Amgen | Biologics | Acute myeloid leukemia | This is being evaluated in an early phase I clinical trial at Amgen for the intravenous treatment of adult patients with relapsed or refractory acute myeloid leukemia. In 2020, the company paused product development while gathering further information on the CD33 program through a progression of AMG-330. |
Phase I | Amphivena Therapeutics | Biologics |
Acute myeloid leukemia; Cancer |
It is a CD33 x CD3 tandem diabody in early clinical development at Amphivena Therapeutics for the treatment of relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndromes and advanced solid tumors. |
For more information about our anti-CD33 recombinant antibody products, please feel free to contact us at any time. Our dedicated team is here to assist you with any inquiries you may have, and we look forward to establishing a mutually beneficial partnership that supports your research goals.